Aims: We wanted to evaluate the effects of a bone anabolic agent (bone morphogenetic protein 2 (BMP-2)) on an anti-catabolic background (systemic or local zoledronate) on fixation of allografted revision implants.
Methods: An established allografted revision protocol was implemented bilaterally into the stifle joints of 24 canines. At revision surgery, each animal received one BMP-2 (5 µg) functionalized implant, and one raw implant. One group (12 animals) received bone graft impregnated with zoledronate (0.005 mg/ml) before impaction. The other group (12 animals) received untreated bone graft and systemic zoledronate (0.1 mg/kg) ten and 20 days after revision surgery. Animals were observed for an additional four weeks before euthanasia.
Results: No difference was detected on mechanical implant fixation (load to failure, stiffness, energy) between local or systemic zoledronate. Addition of BMP-2 had no effect on implant fixation. In the histomorphometric evaluation, implants with local zoledronate had more area of new bone on the implant surface (53%, p = 0.025) and higher volume of allograft (65%, p = 0.007), whereas implants in animals with systemic zoledronate had the highest volume of new bone (34%, p = 0.003). Systemic zoledronate with BMP-2 decreased volume of allograft by 47% (p = 0.017).
Conclusion: Local and systemic zoledronate treatment protects bone at different stages of maturity; local zoledronate protects the allograft from resorption and systemic zoledronate protects newly formed bone from resorption. BMP-2 in the dose evaluated with experimental revision implants was not beneficial, since it significantly increased allograft resorption without a significant compensating anabolic effect. Cite this article: 2021;10(8):488-497.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414437 | PMC |
| http://dx.doi.org/10.1302/2046-3758.108.BJR-2020-0280.R1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Geranylgeranyl diphosphate synthase inhibition impairs osteoclast differentiation, morphology, and resorptive activity.
JBMR Plus
January 2025
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Article Synopsis
- Nitrogen bisphosphonates like zoledronic acid treat osteolytic bone diseases by targeting farnesyl diphosphate synthase (FDPS), but their strong bone affinity limits their systemic use.
- RAM2061, a novel GGDPS inhibitor, shows promising drug-like qualities, such as prolonged half-life and anti-cancer effects in mouse models, and impacts osteoclast biology by disrupting differentiation and function.
- Although RAM2061 treatment didn't significantly affect overall bone turnover in mice, it reduced mature osteoclast numbers, signaling its potential for further investigation in bone remodeling therapies.
Administration and cancer-control outcomes of bone-modifying agents in real-world patients with metastatic castration-resistant prostate cancer.
JBMR Plus
January 2025
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, 63010, Germany.
Hormonal agents administered for metastatic castration-resistant prostate cancer (mCRPC) may lead to osteoporosis, skeletal events, reduced quality of life, and even reduced overall survival (OS). Bone-modifying agents may prevent those events but their effect on cancer-control outcomes remains uncertain. Relying on our institutional tertiary-care database, we explored the effect of bone-modifying agents (bisphosphonates such as zoledronic acid and denosumab) on OS and progression-free survival in patients with mCRPC with at least 1 bone metastasis using Kaplan-Meyer estimates and Cox regression models.
View Article and Find Full Text PDFCombining systemic and local osteoporosis treatments: A longitudinal in vivo microCT study in ovariectomized rats.
Bone
December 2024
Laboratory of Biomechanical Orthopedics, Institute of Bioengineering, EPFL, Lausanne, Switzerland.
Introduction: Managing osteoporotic patients at immediate fracture risk is challenging, in part due to the slow and localized effects of anti-osteoporotic drugs. Combining systemic anti-osteoporotic therapies with local bone augmentation techniques offers a promising strategy, but little is known about potential interactions. We hypothesized that integrating systemic treatments with local bone-strengthening biomaterials would have an additive effect on bone density and structure.
View Article and Find Full Text PDFOsteoporosis in Systemic Mastocytosis: A Scoping Review.
Medicina (Kaunas)
October 2024
Precision Medicine in the Medical, Surgical and Critical Care Areas, University of Palermo, 90100 Palermo, Italy.
: Mastocytosis (MS) is a rare disease that can involve various organs, including the bone. Given the incidence of the disease in the global population, MS poses a challenge for physicians, and early therapeutic intervention in the initial stages could significantly impact the quality of life of affected patients. : The aim of this scoping review was to provide an overview of secondary osteoporosis in systemic mastocytosis (SM), focusing on the heterogeneity of its manifestations, the benefits of early diagnosis, and appropriate pharmacological treatment.
View Article and Find Full Text PDFIncreased bone mass but delayed mineralization: in vivo and in vitro study for zoledronate in bone regeneration.
BMC Oral Health
September 2024
Fujian Key Laboratory of Oral Diseases, School and Hospital of Stomatology, Fujian Medical University, Fujian, China.
Background: Bisphosphonates (BPs) are widely used to inhibit excessive osteoclast activity. However, the potential to compromise bone defect healing has limited their broader application. To better understand the influence of BPs on bone regeneration, we established a bone grafting model with Zoledronate administration, aiming to deepen the understanding of bone remodeling and mineralization processes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!